Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Change in Inventory (2022 - 2025)

Historic Change in Inventory for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to -$47000.0.

  • BioXcel Therapeutics' Change in Inventory rose 9593.07% to -$47000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 11622.72%. This contributed to the annual value of -$1.3 million for FY2024, which is 2196666.67% down from last year.
  • Per BioXcel Therapeutics' latest filing, its Change in Inventory stood at -$47000.0 for Q3 2025, which was up 9593.07% from -$136000.0 recorded in Q2 2025.
  • BioXcel Therapeutics' 5-year Change in Inventory high stood at $713000.0 for Q2 2022, and its period low was -$1.2 million during Q3 2024.
  • Moreover, its 4-year median value for Change in Inventory was -$27000.0 (2023), whereas its average is $30600.0.
  • Data for BioXcel Therapeutics' Change in Inventory shows a peak YoY increase of 145757.58% (in 2024) and a maximum YoY decrease of 303333.33% (in 2024) over the last 5 years.
  • BioXcel Therapeutics' Change in Inventory (Quarter) stood at $577000.0 in 2022, then tumbled by 104.68% to -$27000.0 in 2023, then crashed by 3033.33% to -$846000.0 in 2024, then surged by 94.44% to -$47000.0 in 2025.
  • Its Change in Inventory stands at -$47000.0 for Q3 2025, versus -$136000.0 for Q2 2025 and -$37000.0 for Q1 2025.